Winton Group’s BioXcel Therapeutics BTAI Stock Holding History

Winton Group’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-766	Closed	-$249K	–	972
2021 Q4	$249K	Buy	+766	New	+$329K	0.02%	886

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Winton Group's BTAI Position: Q1 2022 in Review

Winton Group sold out of BioXcel Therapeutics (BTAI) in Q1 2022, closing a stake of 766 shares — an estimated $249K sold.

Winton Group first reported a position in BTAI in Q4 2021 and held it in 1 quarter. The position peaked at $249K in Q4 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

Winton Group reported no remaining BioXcel Therapeutics position as of Q1 2022 after selling out during the quarter.
Winton Group sold 766 BioXcel Therapeutics shares in Q1 2022, an estimated $249K.
Winton Group first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 1 quarter.
Winton Group's BioXcel Therapeutics position peaked at $249K in Q4 2021.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.